Am. J. Respir. Crit. Care Med., Volume 156, Number 1, July 1997, 173-177

Rheology of Cystic Fibrosis Sputum after in vitro Treatment with Hypertonic Saline Alone and in Combination with Recombinant Human Deoxyribonuclease I

MALCOLM KING, BONNIE DASGUPTA, ROBERT P. TOMKIEWICZ,^* and NEIL E. BROWN

Pulmonary Research Group, University of Alberta, Edmonton, Alberta, Canada

Treatment with recombinant human deoxyribonuclease I (rhDNase) is currently used as therapy for cystic fibrosis (CF) lung disease. Hypertonic saline (HS) acts as an expectorant promoting mucus secretion and augmenting the volume of sputum. We evaluated the individual and combined effects of HS and rhDNase in vitro on the viscoelasticity of CF sputum. Sputum samples were collected from nine CF patients to use for in vitro testing. Aliquots of CF sputum (0.20 to 0.40 g) were subjected to the following protocols: (1) negative control sample without any treatment; (2) positive control sample, adding 10% volume of normal saline (0.9% NaCl); (3) application of hypertonic saline (HS-3% NaCl); (4 ) combining approximately 100 nM concentration of rhDNase with protocols 2 and 3. The samples in protocols 2 through 4 were incubated for 30 min at 37° C. For each protocol, CF sputum was analyzed at baseline and at 30 min for spinnability by filancemeter and viscoelasticity by magnetic microrheometry. Spinnability decreased for the sputum samples that were treated with rhDNase, in combination with either HS or normal saline. Treatment with HS alone and combined treatment with rhDNase and HS decreased log G* (the principal viscoelasticity index) to the same degree. Saline alone and rhDNase in normal saline both increased the predicted cough clearability of the sputum; however, the combined treatment with rhDNase and hypertonic saline had the best overall effect on cough clearability. The change in predicted mucociliary clearability, although greatest after HS, was not significant. These in vitro results suggest that combined treatment with rhDNase and HS should be evaluated further as a potential mucotropic approach to augment the clearance of purulent sputum in CF lung disease.

This article has been cited by other articles:

				C. A. Ganoza, J. N. Ricaldi, J. Chauca, G. Rojas, C. Munayco, J. Agapito, J. C. Palomino, and H. Guerra Novel hypertonic saline-sodium hydroxide (HS-SH) method for decontamination and concentration of sputum samples for Mycobacterium tuberculosis microscopy and culture J. Med. Microbiol., September 1, 2008; 57(9): 1094 - 1098. [Abstract] [Full Text] [PDF]

				J. N Ricaldi and H. Guerra A simple and improved method for diagnosis of tuberculosis using hypertonic saline and sodium hydroxide to concentrate and decontaminate sputum Trop Doct, April 1, 2008; 38(2): 97 - 99. [Abstract] [Full Text] [PDF]

				S. H. Donaldson, T. E. Corcoran, B. L. Laube, and W. D. Bennett Mucociliary Clearance as an Outcome Measure for Cystic Fibrosis Clinical Research Proceedings of the ATS, August 1, 2007; 4(4): 399 - 405. [Abstract] [Full Text] [PDF]

				B. K. Rubin, A. P. Kater, and A. L. Goldstein Thymosin {beta}4 Sequesters Actin in Cystic Fibrosis Sputum and Decreases Sputum Cohesivity in Vitro. Chest, November 1, 2006; 130(5): 1433 - 1440. [Abstract] [Full Text] [PDF]

				M. H. Levin, S. Sullivan, D. Nielson, B. Yang, W. E. Finkbeiner, and A. S. Verkman Hypertonic Saline Therapy in Cystic Fibrosis: EVIDENCE AGAINST THE PROPOSED MECHANISM INVOLVING AQUAPORINS J. Biol. Chem., September 1, 2006; 281(35): 25803 - 25812. [Abstract] [Full Text] [PDF]

				I. Aziz, J. A. Kastelik, S. Zarogiannis, C. Hatzoglou, K. Gourgoulianis, R. Kuver, S. P. Lee, P. T.P. Bye, M. R. Elkins, S. H. Donaldson, et al. Hypertonic saline for cystic fibrosis. N. Engl. J. Med., April 27, 2006; 354(17): 1848 - 1851. [Full Text] [PDF]

				M. R. Elkins, M. Robinson, B. R. Rose, C. Harbour, C. P. Moriarty, G. B. Marks, E. G. Belousova, W. Xuan, P. T.P. Bye, and the National Hypertonic Saline in Cystic Fibrosis A Controlled Trial of Long-Term Inhaled Hypertonic Saline in Patients with Cystic Fibrosis N. Engl. J. Med., January 19, 2006; 354(3): 229 - 240. [Abstract] [Full Text] [PDF]

				M. R. Elkins, T. Lane, H. Goldberg, J. Pagliuso, L. A. Garske, E. Hector, L. Marchetto, J. A. Alison, and P. T. P. Bye Effect of airway clearance techniques on the efficacy of the sputum induction procedure Eur. Respir. J., November 1, 2005; 26(5): 904 - 908. [Abstract] [Full Text] [PDF]

				J. X. Tang, Q. Wen, A. Bennett, B. Kim, C. A. Sheils, R. Bucki, and P. A. Janmey Anionic poly(amino acid)s dissolve F-actin and DNA bundles, enhance DNase activity, and reduce the viscosity of cystic fibrosis sputum Am J Physiol Lung Cell Mol Physiol, October 1, 2005; 289(4): L599 - L605. [Abstract] [Full Text] [PDF]

				R. L. Gibson, J. L. Burns, and B. W. Ramsey Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis Am. J. Respir. Crit. Care Med., October 15, 2003; 168(8): 918 - 951. [Abstract] [Full Text] [PDF]

				A. Mandelberg, G. Tal, M. Witzling, E. Someck, S. Houri, A. Balin, and I. E. Priel Nebulized 3% Hypertonic Saline Solution Treatment in Hospitalized Infants With Viral Bronchiolitis Chest, February 1, 2003; 123(2): 481 - 487. [Abstract] [Full Text] [PDF]

				E. M. Sarrell, G. Tal, M. Witzling, E. Someck, S. Houri, H. A. Cohen, and A. Mandelberg Nebulized 3% Hypertonic Saline Solution Treatment in Ambulatory Children With Viral Bronchiolitis Decreases Symptoms Chest, December 1, 2002; 122(6): 2015 - 2020. [Abstract] [Full Text] [PDF]

				P. G. NOONE, W. D. BENNETT, J. A. REGNIS, K. L. ZEMAN, J. L. CARSON, M. KING, R. C. BOUCHER, and M. R. KNOWLES Effect of Aerosolized Uridine-5'-Triphosphate on Airway Clearance with Cough in Patients with Primary Ciliary Dyskinesia Am. J. Respir. Crit. Care Med., July 1, 1999; 160(1): 144 - 149. [Abstract] [Full Text]

				W. FENG, H. GARRETT, D. P. SPEERT, and M. KING Improved Clearability of Cystic Fibrosis Sputum with Dextran Treatment in vitro Am. J. Respir. Crit. Care Med., March 1, 1998; 157(3): 710 - 714. [Abstract] [Full Text] [PDF]